CYBN

Cybin Inc.

Media Advisory – Presentation of the round table on the theme “First Nations and the Economic Development”

TORONTO, Jan. 15, 2021 - Trading resumes in:Company: CYBIN INC.NEO Exchange Symbol: CYBNAll Issues: NoResumption (ET): 10:21:58 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national ... Read More...

Pontus Announces Acquisition of Ephémère Supper Club to Vertically Integrate Product Development

VANCOUVER, BC, Feb. 17, 2021 - Pontus Protein Ltd. ("Pontus" or the "Company") (TSXV: HULK) (FSE: 8YC) is pleased to announce that it has entered into a definitive agreement dated February 16, 2021 (the "Definitive Agreement") to acquire all of the issued and outstanding shares of Ephemere Catering & Consulting Inc. ("Ephémère").Ephém... Read More...

Rogers Cybersecure Catalyst at Ryerson University Announces the Launch of the Catalyst Cyber Range

The Catalyst Cyber Range is a state-of-the-art cybersecurity training and testing platform that will train new cybersecurity workers, upskill existing cybersecurity professionals, and drive cybersecurity research and innovation in CanadaBRAMPTON, ON, Feb. 11, 2021 - Rogers Cybersecure Catalyst at Ryerson University is pleased to announce ... Read More...

Cybin Announces CDN$20 Million Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, Jan. 18, 2021 - Cybin Inc. (NEO: CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. ("... Read More...

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

HIGHLIGHTSUsing Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders.Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal bra... Read More...

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

Cybin to host conference call today, December 7, 2020, at 5:00 p.m. ETTransaction adds extensive intellectual property portfolio and product pipeline to potentially diversify Cybin’s programs and includes multiple additional indications.Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic ... Read More...